摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-甲基-5-溴苯并噻吩 | 1196-09-4

中文名称
3-甲基-5-溴苯并噻吩
中文别名
5-溴-3-甲基-苯并[b]噻吩
英文名称
5-bromo-3-methylbenzo[b]thiophene
英文别名
5-bromo-3-methyl-1-benzothiophene
3-甲基-5-溴苯并噻吩化学式
CAS
1196-09-4
化学式
C9H7BrS
mdl
——
分子量
227.125
InChiKey
YSYLNZAFOPVZLP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    40-41℃
  • 沸点:
    151-152 °C(Press: 10 Torr)
  • 密度:
    1.561

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    28.2
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2934999090
  • 储存条件:
    存储条件:2-8°C,避光保存。

SDS

SDS:48f376523a4c38ce96b4f686f1f4bbc3
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Bromo-3-methylbenzo[b]thiophene
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-3-methylbenzo[b]thiophene
CAS number: 1196-09-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7BrS
Molecular weight: 227.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    3-甲基-5-溴苯并噻吩N-甲基吡咯烷酮 为溶剂, 以0.76 g (85%)的产率得到3-甲基-5-氰基苯并噻吩
    参考文献:
    名称:
    Triazole containing indole derivatives
    摘要:
    一类取代的咪唑、三唑和四唑衍生物是5-HT.sub.1 -样受体的选择性激动剂,因此在治疗临床疾病中特别有用,尤其是偏头痛和相关的紊乱,对于这些疾病,需要使用这些受体的选择性激动剂。
    公开号:
    US05298520A1
  • 作为产物:
    描述:
    1-(4-bromophenylthio)propan-2-one 在 Polyphosphoric acid on Celite 作用下, 以 甲苯 为溶剂, 反应 24.0h, 以92%的产率得到3-甲基-5-溴苯并噻吩
    参考文献:
    名称:
    苯并[ b ]噻吩。衍生产品。二十八。5-溴-3-苯并[ b ]噻吩丙氨酸及其衍生物†
    摘要:
    已经合成了镰刀型血红蛋白潜在的胶凝抑制剂5-溴-3-苯并[ b ]噻吩丙氨酸及其几种衍生物。已经研究了从中间体5-溴-3-苯并[ b ]噻吩基甲酰胺基甲酸酯的几种水解途径,其中涉及醇解至N-甲酰基-5-溴-3-苯并[ b ]噻吩丙氨酸的水解途径显示出优越的水解途径。
    DOI:
    10.1002/jhet.5570210430
点击查看最新优质反应信息

文献信息

  • BENZOTHIOPHENE INHIBITORS OF RHO KINASE
    申请人:Kahraman Mehmet
    公开号:US20080021026A1
    公开(公告)日:2008-01-24
    The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.
    本发明涉及化合物和方法,这些化合物和方法可能作为Rho激酶的抑制剂在治疗或预防疾病方面有用。
  • [EN] SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS SPIRO-OXADIAZOLINE EN TANT QU'AGONISTES DES RÉCEPTEURS DE L'ACÉTYLCHOLINE Α-7 NICOTINIQUE
    申请人:FORUM PHARMACEUTICALS INC
    公开号:WO2015066371A1
    公开(公告)日:2015-05-07
    The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
    本发明涉及新型螺环-噁二唑啉化合物,适用作a7-nAChR的激动剂或部分激动剂,以及这些化合物和组合物的制备方法、药物组合物,以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物。具体而言,涉及向需要的患者(例如患有认知缺陷和/或希望增强认知功能的患者)施用螺环-噁二唑啉cx7-nAChR激动剂或部分激动剂的方法,以使其获益。
  • Indole derivatives for the treatment of depression and anxiety
    申请人:——
    公开号:US20040006229A1
    公开(公告)日:2004-01-08
    The present invention provides compounds of formula (I): which are useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. 1
    本发明提供了以下化合物的公式(I):这些化合物对治疗抑郁症、焦虑症,并缓解因戒烟或部分戒烟引起的症状非常有用。
  • Discovery and Structure–Activity Relationships of <i>N</i> ‐Aryl 6‐Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors
    作者:Nicolas Boutard、Arkadiusz Białas、Aleksandra Sabiniarz、Paweł Guzik、Katarzyna Banaszak、Artur Biela、Marcin Bień、Anna Buda、Barbara Bugaj、Ewelina Cieluch、Anna Cierpich、Łukasz Dudek、Hans‐Michael Eggenweiler、Joanna Fogt、Monika Gaik、Andrzej Gondela、Krzysztof Jakubiec、Mirek Jurzak、Agata Kitlińska、Piotr Kowalczyk、Maciej Kujawa、Katarzyna Kwiecińska、Marcin Leś、Ralph Lindemann、Monika Maciuszek、Maciej Mikulski、Paulina Niedziejko、Alicja Obara、Henryk Pawlik、Tomasz Rzymski、Magdalena Sieprawska‐Lupa、Marta Sowińska、Joanna Szeremeta‐Spisak、Agata Stachowicz、Mateusz M. Tomczyk、Katarzyna Wiklik、Łukasz Włoszczak、Sylwia Ziemiańska、Adrian Zarębski、Krzysztof Brzózka、Mateusz Nowak、Charles‐Henry Fabritius
    DOI:10.1002/cmdc.201800569
    日期:2019.1.8
    is the ubiquitous and hypoxia‐induced isoform of PFK‐2, are reported. X‐ray crystallography and docking were instrumental in the design and optimisation of a series of Naryl 6‐aminoquinoxalines. The most potent representative, N‐(4‐methanesulfonylpyridin‐3‐yl)‐8‐(3‐methyl‐1‐benzothiophen‐5‐yl)quinoxalin‐6amine, displayed an IC50 of 14 nm for the target and an IC50 of 0.49 μm for fructose‐2,6‐biphosphate
    癌细胞的能量和生物质生产在很大程度上被有氧糖酵解所支持,这就是所谓的Warburg效应。该过程受关键酶的调节,其中磷酸果糖激酶PFK-2通过产生果糖-2,6-二磷酸而起重要作用。磷酸果糖激酶PFK-1执行的最有效的糖酵解限速步骤激活剂。本文介绍了6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酯酶3(PFKFB3)的新型抑制剂的合成,生物学评估以及其结构与活性之间的关系,PFKFB3是一种普遍存在且由低氧引起的PFK-2亚型,被报道。X射线晶体学和对接有助于设计和优化一系列N-芳基6-氨基喹喔啉。最有力的代表,N-(4-甲磺酰基吡啶-3-基)-8-(3-甲基-1-苯并噻吩-5-基)喹喔啉-6-胺,目标物的IC 50为14 n m,0.4的IC 50为0.49μm m为人类结肠癌HCT116细胞中果糖2,6-二磷酸的产生。这项工作为PFKFB3抑制剂领域的发展提供了新的机会。
  • [EN] PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE UTILISÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DES PGE2
    申请人:IDORSIA PHARMACEUTICALS LTD
    公开号:WO2018210988A1
    公开(公告)日:2018-11-22
    The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    本发明涉及式(I)的嘧啶衍生物,其中(R1)n,R3,R4a,R4b,R5a,R5b和Ar1如描述中所述,以及它们通过调节免疫反应,包括肿瘤中免疫系统的再激活,用于治疗癌症。本发明进一步涉及新颖的苯并呋喃和苯并噻吩衍生物式(II),及其作为药物的使用,其制备,药用可接受的盐,及其作为药物的使用,以及包含式(I)中一个或多个化合物的药物组合物,尤其是它们作为前列腺素2受体EP2和/或EP4的调节剂的使用。
查看更多

同类化合物